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Urticaria and angioedema lasting more than 6 weeks have
been designated as chronic urticaria (CU). It encompasses
two major subtypes: chronic spontaneous urticaria (CSU)
(previously known as chronic idiopathic urticaria) (CIU)
and chronic inducible urticaria. CSU has been defined
as wheals and/or angioedema that are endogenous and
independent of any external physical stimulus. It affects
0.5 to 1% of the population [1]. In 40 to 45% of patients
with CSU autoantibodies to the high affinity IgE receptor
(FcεRI) or to IgE itself are thought to play a psathogenic
role, whereas 55 to 60% of cases are considered idiopathic
[2]. Inducible urticarias include all forms of physical
urticarias (cold-induced, heat-induced, solar, and pressure
urticaria).
According to the International Guidelines for the man-
agement of urticaria and angioedema non-sedating, second
generation antihistamines (NSAHs) are recommended
for the treatment of CU [3]. Nevertheless, a considerable
proportion of patients do not respond sufficiently to
NSAHs. According to Humphreys and Hunter up to
40% of patients with CU may not achieve good control
with antihistaminic therapy [4]. They reported that out
of 390 CU patients who were treated with antihistamines
44% responded well, 29% became asymptomatic, and
15% showed partial improvement. In a recent paper
from Japan it was observed that the improvement rates
(defined as a urticaria symptom score UAS ≤ 3) in 117
CU patients who received standard doses of AHs were* Correspondence: sanchezbmario@gmail.com
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article, unless otherwise stated.36.6% at 12 months, 51.2% at 24 months, and 66.1% at
60 months, while the remission rates were 11.5%, 13.9%,
and 27.7%, respectively [5].
In patients that do not respond to standard doses, the
next step in guideline-based therapy is to increase AH
doses up to 4 times [3]. Investigations assessing the
response to various NSAHs have demonstrated that
up-dosing is significantly more effective in reducing
symptoms of CU than standard-dose treatment [6].
According to Kaplan, high-dose antihistamines are effect-
ive in 45-60% of patients with CSU [7], while about one
third are antihistamine resistant regardless of which dose
is used [8,9].
The present article is a review of the literature on the
treatment of CU with increased doses of NSAHs in order
to investigate if there are differences in efficacy between
the various second generation AHs that have been studied
in controlled protocols. It must be noticed, however,
that it is difficult to find clinical investigations that
strictly follow the criteria recommended by the guidelines
on the management of urticaria, and therefore studies
included in this review were those in which higher doses
of NSAHs were used regardless of the clinical response to
conventional doses.
AHs included in this review are desloratadine, levoce-
tirizine, fexofenadine, and the recently introduced NSAHs
rupatadine and bilastine. Bilastine belongs to the piperidine
class of antihistamines as do loratadine, desloratadine, and
fexofenadine. Like other antihistamines bilastine is an H1
receptor inverse agonist. In vitro studies have shown that
bilastine has a high specific affinity for the H1-receptor but
it has no or very low affinity for 30 other tested receptors.
The affinity for the H1 receptor is 3 and 6 times higherCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Studies included in this comparative analysis










Finn 1999 Fexofenadine DB,PC 28 CSU/CIU 439 MPS 17
Nelson 2000 Fexofenadine R,DB,PC 28 CSU/CIU 418 MPS 18
Giménez-Arnau 2007 Rupatadine R,DB,PC 28 CSU/CIU 329 MPS 19
Dubertret 2007 Rupatadine R,DB,PC 28 CSU/CIU 277 MPS 20
Siebenhaar 2009 Desloratadine R,DB,PC 7 ACU 30 % SF 21
Staevska 2010 Desloratadine DB,PC 28 CSU/CIU 40 % SF 22
Staevska 2010 Levocetirizine DB,PC 28 CSU/CIU 40 % SF 22
Krause 2013 Bilastine R,DB,PC 7 ACU 20 % SF 23
DB double-blind, PC placebo-controlled, R randomized.
CSU chronic spontaneous urticaria, CIU chronic idiopathic urticaria, ACU acquired cold urticaria.
MPS mean pruritus score, % SF percentage of symptom-free patients.
Table 2 Efficacy of increased doses of non-sedating
antihistamines in patients with chronic urticaria
Efficacy
Authorref Drug Dose (mg) Responders/n %
Finn [17] Fexofenadine 120 BD 46/89 51.6
Finn [17] Fexofenadine 240 BD 54/83 64.9
Nelson [18] Fexofenadine 120 BD 33/77 42.8
Nelson [18] Fexofenadine 240 BD 46/82 56.0
Giménez-Arnau [19] Rupatadine 20 QD 69/109 63.3
Dubertret [20] Rupatadine 20 QD 48/67 71.6
Siebenhaar [21] Desloratadine 20 QD 15/30 50.0
Staevska [22] Desloratadine 10 QD 7/36 19.4
Staevska [22] Desloratadine 20 QD 1/29 3.4
Staevska [22] Levocetirizine 10 QD 8/31 25.8
Staevska [22] Levocetirizine 20 QD 5/23 21.7
Krause [23] Bilastine 40 QD 11/20 55.0
Krause [23] Bilastine 80 QD 12/20 60.0
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Rupatadine fumarate is a new potent, long acting, orally
active dual antagonist of both histamine H1 and Platelet-
Activating Factor (PAF) receptors. In in vivo and in vitro
studies rupatadine was as potent or even more potent
than other second generation antihistamines (loratadine,
terfenadine and cetirizine) or selective PAF antagonists [12].
Methods
A literature search of PubMed/MEDLINE looking spe-
cifically at the studies that investigated the effects of in-
creased doses of NSAHs in patients with all subtypes of
CU was conducted. For analysis of the efficacy, only
double-blind, placebo-controlled studies were selected,
whereas uncontrolled studies were excluded.
Data on study drug, doses, study design, treatment
duration, subtype of urticaria being treated, number of
patients, and main parameter of efficacy, were collected.
When available, efficacy data were pooled from different
studies that utilized the same drug dose. The proportions
of patients responding to the therapy were compared using
the Fisher’s exact test with a significance level of p < 0.05.
Results
Twelve studies that investigated the effects of higher
doses of NSAHs were identified in this search. Among
those, 3 papers dealing with the treatment of patients
with CSU were excluded from analysis because of their
open design, 2 employing cetirizine and one that utilized
ebastine [13-15]. Another study by Metz et alwas also
excluded because it assessed exclusively the effects of a
20 mg dose of rupatadine in patients with acquired cold
urticaria whereas no comparisons with other doses of
the drug were done [16].
Table 1 summarizes the details from 8 double-blind,
placebo-controlled studies included in this report. Two in-
vestigations used fexofenadine, rupatadine, or desloratadine,
and one study was done with levocetirizine or bilastine. Inmost studies NSAHs were administered for 28 days,
although in the papers by Siebenhaar (with desloratadine)
and Krause (with bilastine) the drugs were given for 7 days.
Six articles included patients with CSU/CIU and other 2
studied patients with acquired cold urticaria. Four investi-
gations chose mean pruritus scores as the main outcome,
and the other 4 utilized the percentage of symptom-free
patients as the main parameter of efficacy.
Table 2 presents the results of the 8 studies in regard
to efficacy of the treatment. It can be observed that the
proportion of symptom improvement was highly variable,
ranging from 3.4% to 71.6%, depending on the drug and
dose. The best responses were obtained with fexofenadine,
rupatadine, and bilastine.
The statistical comparison of the data is shown in
Figure 1. There were not significant differences in effi-
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Figure 1 Efficacy of increased doses of nonsedating antihistamines in patients with chronic urticaria. A) According to mean pruritus
score (MPS). *Fexofenadine 120 mg vs Fexofenadine 240 mg p = 0.01, ¶ Fexofenadine 120 mg vs Rupatadine 20 mg p = 0.0001, ♦ Fexofenadine
240 mg vs Rupatadine 20 mg p = 0.03. B) According to percentage of symptom-free patients. * Desloratadine 10 mg vs Desloratadine 120 mg,
Desloratadine 10 mg vs Levocetirizine 10 mg, Desloratadine 10 mg vs Levocetirizine 20 mg, Desloratadine 20 mg vs Levocetirizine 10 mg, Desloratadine
20 mg vs Levocetirizine 20 mg, Levocetirizine 10 mg vs Levocetirizine 20 mg, Bilastine 40 mg vs Bilastine 80 mg p n.s. ¶ Desloratadine 10 mg vs Bilastine
40 mg p = 0.006. ♦ Desloratadine 10 mg vs Bilastine 80 mg p = 0.002. ♠ Desloratadine 20 mg vs Bilastine 40 mg, Desloratadine 20 mg vs Bilastine 80 mg,
Levocetirizine 10 mg vs Bilastine 40 mg p = 0.02. ♣ Levocetirizine 10 mg vs Bilastine 80 mg p = 0.01.
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fexofenadine, rupatadine, and bilastine showed signifi-
cantly higher efficacy than desloratadine or levocetirizine,
and rupatadine had higher efficacy than fexofenadine.
Discussion
According to current recommendations, patients with
CU who do not respond to licensed doses of NSAHs
should be switched to higher doses in order to obtain a
better disease control. A number of publications that
evaluated different NSAHs in increasing doses have
clearly demonstrated that a higher proportion of patients
previously uncontrolled exhibit significant improvements
of their symptoms after going through this approach [6].
It is important to mention that these enhanced resultshave generally been accomplished without compromising
patient’s safety, since no increased rates of side effects,
including somnolence, have been observed.
The mechanisms explaining patient’s benefits from
up-dosing are not completely understood, but increased
in vivo receptor occupancy [24,25], and effects of anti-
histamines on additional receptors have been proposed
[26]. Observed differences in response to different NSAHs
cannot be explained by terminal elimination half-life,
duration of action, higher tissue/plasma concentration
ratios or the presence of active metabolites in the skin
[27]. An alternative hypothesis would be a differential
H1-receptor occupancy by free (unbound) H1 antihista-
mine [25,28]. The results discussed in present paper are
in agreement with a previous report by Church and
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an indicator of anti-H1 antihistamine potency in vitro,
the large differences in volume of distribution and tissue
accumulation in humans preclude this from being a good
predictor of clinical efficacy in CSU.
In a previous review article we had proposed that
favorable responses to high doses of NSAHs in patients
with CU were not uniformly observed, and it was likely
that there would be dissimilar results when outcomes
from different studies were compared [6]. Present art-
icle shows that in fact some higher doses of NSAHs,
notably fexofenadine, rupatadine, and bilastine, induced
better objective improvements than desloratadine and
levocetirizine (Table 2, Figure 1). The reasons for these
differences are not clear at this time, but may depend
on differential properties of the drugs, such as their
chemical structure, in vivo anti-inflammatory actions,
metabolism, blockade of various receptors, and interac-
tions with transporter systems (e.g., P-glycoprotein) [30].
In the case of fexofenadine, however, two studies demon-
strated that higher doses were not more efficacious than
the standard 60 mg twice a day dose [17,18].
Since more than 30% of CU patients are refractory to
antihistamine therapy, additional pharmacological strat-
egies are available. Alternative drugs inducing better
responses in AH-resistant CU, as based on scientific
evidences, include the addition of leukotriene receptor
antagonists, corticosteroids, cyclosporine, or omalizumab
[7,31,32]. The choice of alternative, off-label agents,
should be based on availability, relative safety, and socio-
economic considerations.
When administering high doses of antihistamines
questions on their safety are usually put forward. Studies
conducted up to now have not demonstrated important
concerns on predictable or newer adverse effects of up
to 4 times recommended doses of NSAHs. Headache
was the most frequent adverse effect reported for fexofe-
nadine [17] and rupatadine [19], but its incidence was
not higher than in placebo-treated patients. Somnolence,
drowsiness, or sedation was uncommon, although for
patients treated with rupatadine 20 mg somnolence was
observed more often than in the placebo group in two
studies [19,20]. The utilization of increased doses of
desloratadine, levocetirizine, and bilastine has not been
associated with adverse effects. Additionally, Staevska et
al reported that patients taking higher doses of levocetir-
izine or desloratadine showed a paradoxical decrease
in somnolence that was attributed to the relief from
urticaria-related discomfort leading to a better quality
of sleep although an alternative explanation would be
the development of tolerance to the central nervous
sedative effects of the antihistamines [22].
The results presented in this paper must be taken
into consideration cautiously because there is a largeheterogeneity between studies included in regard to various
aspects of the investigation such as the subtype of chronic
urticaria under study, duration of the treatment, study
design, drug doses, and primary outcomes.
We can conclude that increased doses of NSAHs show
an improved efficacy in patients with CU who do not
respond to approved doses. According to the studies
presented in this paper, this conclusion would be ap-
plicable to CSU/CIU and acquired cold urticaria, but
more research would be necessary to be able to elucidate
if this approach is valid for other types of urticaria. There
are differences in efficacy of these drugs that should be
taken into account in the clinical setting. The use of
double approved doses of fexofenadine, rupatadine, or
bilastine shows an objective improvement in most (>50%)
of patients that respond to antihistamines. Desloratadine
requires four times the approved dose to reach similar
results.
There is still the need for additional studies designed
to investigate the response to high doses of NSAHs in
patients who do not respond to recommended doses,
adapted to current guideline recommendations.Competing interests
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